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Abstract
Introduction
Indexes derived from spontaneous heart period (HP) and systolic arterial pressure (SAP)
fluctuations can detect autonomic dysfunction in individuals with type 2 diabetes mellitus
(DM) associated to cardiovascular autonomic neuropathy (CAN) or other neuropathies. It is
unknown whether HP and SAP variability indexes are sensitive enough to detect the auto-
nomic dysfunction in DM patients without CAN and other neuropathies.
Methods
We evaluated 68 males aged between 40 and 65 years. The group was composed by DM
type 2 DMwith no manifest neuropathy (n = 34) and healthy (H) subjects (n = 34). The proto-
col consisted of 15 minutes of recording of HP and SAP variabilities at rest in supine position
(REST) and after active standing (STAND). The HP power in the high frequency band (HF,
from 0.15 to 0.5 Hz), the SAP power in the low frequency band (LF, from 0.04 to 0.15 Hz)
and BRS estimated via spectral approach and sequence method were computed.
Results
The HF power of HP was lower in DM patients than in H subjects, while the two groups
exhibited comparable HF power of HP during STAND. The LF power of SAP was similar in
DM and H groups at REST and increased during STAND in both groups. BRSs estimated in
the HF band and via baroreflex sequence method were lower in DM than in H and they
decreased further during STAND in both populations.
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Conclusion
Results suggest that vagal control of heart rate and cardiac baroreflex control was impaired
in type 2 DM, while sympathetic control directed to vessels, sympathetic and baroreflex
response to STAND were preserved. Cardiovascular variability indexes are sensitive
enough to typify the early, peculiar signs of autonomic dysfunction in type-2 DM patients
well before CAN becomes manifest.
Introduction
Type 2 diabetes mellitus (DM) has increased its prevalence worldwide and it has been consid-
ered as a public health problem due to its huge impact on the life quality and expectancy of the
individual and on the community in relation to the high cost of its control, management and
treatment [1,2]. When type 2 DM is associated to cardiovascular autonomic neuropathy
(CAN), an autonomic dysfunction is expected and usually detected [3–8]. However, it is
unknown whether the autonomic dysfunction should be considered a consequence of the man-
ifestation of neuropathy or a primary effect of type 2 DM and, if an autonomic dysfunction can
be exclusively linked to type 2 DM, it can be detected via the analysis of the spontaneous fluctu-
ations of heart period (HP) and systolic arterial pressure (SAP) [9].
The early diagnosis of the autonomic dysfunction is very important and it must be done
preferably before CAN become manifest to favor its early management and prevention of seri-
ous consequences including the risk of cardiovascular morbidity and mortality [10]. Some
studies showed that indexes derived from spontaneous fluctuations of HP and SAP, including
univariate and bivariate markers, have a higher sensitivity and specificity than conventional
autonomic function tests in detecting the autonomic dysfunction in DM patients [3–5]. Indeed,
spectral HP and SAP indexes and BRS estimates were found to be significantly modified in DM
individuals [3,6–8].
In this context, studies evaluating the autonomic function in individuals with type 2 DM
without CAN and asymptomatic for any other type of neuropathy might be important to clar-
ify the primary effect of type 2 DM on the cardiovascular control and facilitate the early man-
agement of this pathology. Therefore, we hypothesized that autonomic indexes derived from
SAP and HP spontaneous fluctuations in individuals with type 2 DM without CAN and
asymptomatic for any other type of neuropathy can indicate the early impairment of the car-
diac control.
According to the hypothesis we computed spectral HP and SAP variability indexes and BRS
estimates [11–13] in individuals with type 2 DM without CAN and asymptomatic for any
other type of neuropathy at rest in supine position (REST) and during active standing
(STAND). STAND was exploited to probe the ability of the cardiovascular control to cope with
a typical stressor of the cardiovascular system (i.e. the reduction of the venous return in relation
to the modification of posture) via a vagal inhibition and sympathetic activation [14–17].
Materials and Methods
Population
We evaluated 68 males, aged between 40 and 65 years (Table 1). Table 2 reported the medica-
tions relevant to the considered population. The group was composed by patients with DM
without neuropathy (n = 34) and healthy (H) subjects (n = 34). They were all non-smokers and
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non-habitual drinkers. Additional exclusion criteria were as follows: ECG with alterations,
and/or myocardial ischemia and/or cardiovascular pathologies, abnormalities in the respira-
tory, neurological, and osteomyoarticular systems, use of illicit drugs or any medications
known to interfere with cardiovascular control and diagnosis of any manifest neuropathy. The
following standard criteria were used to exclude from our DM patients those with CAN: resting
heart rate larger than 100 beats per minute, abnormal value of slow deep breathing autonomic
test, anomalous value of the 30:15 ratio of heart rate in response to STAND, abnormal heart
rate response to the Valsalva maneuver (i.e. the typical ratio of the longest HP to the shortest
one is usually larger than 1.2), atypical orthostatic hypotension in reaction to STAND (the nor-
mal response is a fall of SAP less than 10 mmHg) [18,19]. The absence of peripheral neuropa-
thy and other type of neuropathies was checked by evaluating the sensitivity to 10.0 g Semmes-
Weinstein monofilament and by clinical anamnesis [20].
This study was carried out in according to the Declaration of Helsinki for medical research
involving humans. All subjects were informed about the experimental procedures, read and
signed an informed consent form. This study was approved by the Human Research Ethics
Committee of the Federal University of São Carlos, Brazil (n. 35068814.2.0000.5504).
Experimental protocol
The volunteers were instructed to avoid consuming food and/or drinking stimulating or alco-
holic beverages as well as practicing moderate or heavy exercise within 24 hours before the
Table 1. Characteristics of population.
Characteristics H DM
Age (years) 54.50 ± 5.96 54.0 ± 6.05
Body mass (Kg) 78.97 ± 12.35 82.08 ± 13.29
Height (m) 1.72 ± 0.07 1.72 ± 0.08
BMI (Kg/m2) 26.74 ± 3.49 27.92 ± 3.93
Time of diabetes (years) - 10.99 ± 7.65
HR (bpm) 65.41 ± 9.96 69.74 ± 8,69*
SAP (mmHg) 120.5 (111–126) 131.5 (125–146)*
DAP (mmHg) 68.74 ± 6.37 74.15 ± 8,83*
Laboratory Exams
CRP (mg/dL) 0.84 (0.54–1.96) 1.08 (0.41–2.48)
HbA1c (%) 5.5 (5.3–5.7) 7.7 (6.8–8.7)*
Fasting plasma glucose (mg/dL) 112.6 (96.9–145.5) 174.2 (119.7–343)*
Insulin 5.85 (4.25–7.55) 10.75 (6.40–14.40)*
Total Cholesterol (mg/dL) 204 ± 37.46 209 ± 43.09
HDL-Cholesterol (mg/dL) 48.0 (39.0–52.5) 42.0 (36.0–48.0)
LDL-Cholesterol (mg/dL) 128.16 ± 32.29 127.39 ± 41.83
VLDL-Cholesterol (mg/dL) 23.0 (18.25–31.75) 36.0 (23.75–43.00)
Triglycerides (mg/dL) 119 (92.5–166.5) 184 (119.0–216.0)*
Risk factors
Hypertension - 15 (44.12%)
H = group with healthy subjects; DM = group with type 2 diabetes without neuropathy; BMI = body mass index; CRP = C-reactive protein;
HbA1c = glycated hemoglobin; HR = heart rate at rest in supine position; SAP = systolic arterial pressure at rest in supine position; DAP = diastolic arterial
pressure at rest in supine position. The data are presented in mean ± standard deviation or medians and ﬁrst-to-third quartile range in parentheses.
The symbol * indicates a p < 0.05 (H vs DM).
doi:10.1371/journal.pone.0148903.t001
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evaluation. All the experimental procedures were carried out in the morning in temperature-
controlled room (22–23°C) with a relative air humidity of 50–60%, at the Cardiovascular Phys-
iotherapy Laboratory at the Federal University of São Carlos, São Carlos, Brazil. Only blood
collection was performed at the Clinical Analysis Laboratory. The subjects were first inter-
viewed and examined to verify if they had a regular night sleep and if they were in good health.
Then, blood collection was made before starting the experimental procedures. Half one hour
was allowed between the blood collection and the beginning of the protocol. During this period
the subject consumed a light breakfast in the laboratory. Before starting the protocol, all volun-
teers were familiarized with equipment and facilities of the laboratory. The subjects were
instructed to lie in the supine position, breath spontaneously, and avoid moving and/or talking
during the experiment. The ECG from lead II was recorded (BioAmp Power Lab, ADInstru-
ments, Australia) together with continuous plethysmographic arterial pressure from the mid-
dle finger of left hand (Finometer PRO, Finapress Medical System, The Netherlands) and
respiratory movements by thoracic belt (Marazza, Monza, Italy). All signals were simulta-
neously digitalized with a sampling rate of 1 KHz (Power Lab, ADInstruments, Australia). All
subjects remained at REST for 15 minutes to stabilize the cardiovascular parameters before
starting the recording. The arterial pressure signal was cross-calibrated using a measure pro-
vided by a sphygmomanometer at the onset of the REST. The auto-calibration procedure of
the arterial pressure device was switched off after the first automatic calibration at the onset of
the session. The recording at REST lasted 15 minutes. After this, the volunteers were instructed
to modify their posture to STAND and remain in this position from 15 minutes.
Extraction of the beat-to-beat variability series
After detecting the R-wave peak on the ECG, its apex was located using a parabolic interpola-
tion. The temporal distance between two consecutive R-wave apexes was computed and
Table 2. Medications in the considered population.
Medications H DM
Diabetes medications - 34 (100%)
Metformin - 11 (32.35%)
DPP-4 inhibitor - 1 (2.94%)
Insulin - 3 (8.82%)
Metformin + Sulfonylureas - 10 (29.41%)
Metformin + DPP-4 inhibitor - 2 (5.88%)
Metformin + Sulfonylureas + DPP-4 inhibitor - 1 (2.94%)
Metformin + Insulin - 6 (17.65%)
Antihypertensive drugs - 15 (44.12%)
ACE inhibitor - 3 (8.82%)
Calcium channel blocker (amlodipina) - 1 (2.94%)
Angiotensin II receptor antagonist - 6 (17.65%)
Hydrochlorothiazide - 1 (2.94%)
Hydrochlorothiazide + ACE inhibitor - 2 (5.88%)
Hydrochlorothiazide + Angiotensin II receptor antagonist - 2 (5.88%)
Hypolipidemic drug - 9 (14.71%)
H = group with healthy subjects; DM = group with type 2 diabetes without neuropathy; ACE = angiotensin
converting enzyme; DPP-4 = Dipeptidyl peptidase-4. The data are presented as number of subjects and
percentage between rounded parentheses.
doi:10.1371/journal.pone.0148903.t002
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utilized as an approximation of HP [21]. The maximum of arterial pressure (AP) inside HP
was defined as SAP, and the i-th SAP [i.e., SAP(i)] was taken inside the i-th HP [i.e., HP(i)],
where i is the cardiac beat counter.
The occurrences of the R-wave and SAP peaks were carefully checked to avoid erroneous
detections or missed beats. If isolated ectopic beats affected HP and SAP values, these measures
were linearly interpolated using the closest values unaffected by ectopic beats. HP = {HP(i),
i = 1,. . .,N} and SAP = {SAP(i), i = 1,. . ., N} were extracted on a beat-to-beat basis, where N is
the series length. Synchronous sequences of N = 256 consecutive HP and SAP measures were
selected in a random position inside the REST and STAND periods. The length of the series
was chosen to fulfill the requirements of short-term cardiovascular variability analysis [9] and
to speed up fast Fourier transform exploited to build the surrogate set utilized to test the signifi-
cance of the HP-SAP association. The series were linearly detrended. If evident nonstationari-
ties, such as very slow drifting of the mean or sudden changes of the variance, were visible
despite the linear detrending, the random selection was carried out again. The stationarity of
mean and variance of the selected sequences was finally tested according to [22]. Analysis dur-
ing STAND was performed after five minutes from the onset of the maneuver to facilitate the
detection of stationary sequences. The mean of HP and SAP, μHP and μSAP, and the variance of
HP and SAP, σ2HP and σ
2
SAP, were computed and expressed as ms, mmHg, ms
2 and mmHg2.
Power spectral analysis
The power spectrum was estimated according to a univariate parametric approach fitting the
series according to an autoregressive model [21]. The autoregressive spectral density was fac-
torized into components, each of them characterized by a central frequency. A spectral compo-
nent was labeled as low frequency (LF, from 0.04 to 0.15 Hz) or high frequency (HF, from 0.15
to 0.4 Hz) if its central frequency belonged to the LF or HF band. The LF and HF powers were
defined as the sum of the powers of all LF and HF spectral components, respectively [9]. The
HF power of HP series was expressed in absolute units (ms2), indicated as HFHP. The HFHP
power reflects vagal modulation directed to the heart [23], whereas the LF power of SAP series,
expressed in absolute units (mmHg2) and indicated as LFSAP, reflects efferent sympathetic
modulation directed to vessels [11]. The LF and HF bands of HP and SAP series was calculated
and utilized to compute the BRS in the frequency domain.
Frequency domain BRS assessment
The computation of frequency domain BRS was based on spectral approach [12]. The BRS was
calculated as the square root of the ratio of LFHP to LFSAP power, indicated as αLF, and as the
square root of the ratio of HFHP to HFSAP power, indicated as αHF [24]. The BRS indexes were
expressed in ms/mmHg. To be reliably estimated αLF and αHF HP and SAP variabilities must
be significantly associated with HP fluctuations lagging behind SAP variations [25,26]. The ful-
fillment of this condition was tested according to the calculation of squared coherence
(K2HP-SAP) and phase spectrum (PhHP-SAP). K
2
HP-SAP was computed as the ratio of the square
HP-SAP cross-spectrum modulus divided by the product of the power spectra of HP and SAP
series, while PhHP-SAP was the phase of the HP-SAP cross-spectrum [27]. K
2
HP-SAP, expressed
in dimensionless units, ranged from 0 to 1 indicating a perfect uncorrelation and a full correla-
tion respectively. PhHP-SAP, expressed in radians, ranged between +π and –π radians indicating
both phase opposition. K2HP-SAP and PhHP-SAP were sampled in correspondence of the
weighted average of the central frequencies of the LF and HF components found in the SAP
series (the weights were the powers of the components) and indicated as K2HP-SAP(LF),
K2HP-SAP(HF), PhHP-SAP(LF) and PhHP-SAP(HF) respectively. We checked that at the frequency
Cardiovascular Oscillations Analysis in Type 2 Diabetes
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of interest K2HP-SAP was larger than a threshold computed according to a set of 100 isospectral
isodistributed uncoupled SAP and HP surrogates [27] and PhHP-SAP was negative, thus assur-
ing that HP and SAP series were significantly coupled and HP fluctuations lagged behind SAP
changes.
Time domain BRS assessment
The time domain of BRS was based on sequence method [13] as implemented in [24]. The bar-
oreflex sequence technique relies on the scanning of the HP and SAP series in the search for
sequences with length of four consecutive beats characterized by the contemporaneous increase
(up sequence) or decrease (down sequence) of HP and SAP and referred to as baroreflex
sequences. Only sequences with the following features were labeled as baroreflex sequences: 1)
the total HP variation was larger than 5 ms; 2) the total SAP variation was larger than 1
mmHg; and 3) the correlation coefficient in the plane [SAP(i),HP(i)] was larger than 0.85. The
slope of the regression line in the plane [SAP(i),HP(i)] was calculated and averaged over all
BRS sequences and indicated as αSEQ. BRS was also calculated by separating the up sequences
from the down ones.
Statistical analysis
Normality of the data distribution was verified by the Kolmogorov-Smirnov test. The unpaired
t test, or Mann-Whitney test when applicable, was used to compare characteristics of the popu-
lation and results of the laboratory exams. Two ways analysis of variance was utilized to com-
pare univariate and bivariate time and frequency domain indexes between groups within the
same experimental condition and between experimental conditions within the same group
(Holm-Sidak test for multiple comparisons, one factor repetition). The data were analyzed
using a commercial statistical program (Sigmaplot, ver.11.0, Systat Software, San Jose, CA,
USA). A p<0.05 was always considered to be significant.
Results
Table 1 shows age, anthropometric characteristics, heart rate, SAP and diastolic arterial pres-
sure, results of the laboratory exams and risk factors. Table 2 reports medications of the DM
population. H and DM groups were different in relation to glycated hemoglobin (HbA1c), fast-
ing plasma glucose, insulin and triglycerides. Heart rate, SAP and diastolic arterial pressure
were higher in DM patients than in H subjects.
Time and frequency domain HP and SAP parameters
The grouped bargraphs of Fig 1 show the results of time and frequency domain analyses of HP
and SAP series as a function of the group (i.e. H and DM individuals) at REST (black bars) and
during STAND (white bars). Values are given as mean plus standard deviation. The μHP
decreased significantly during STAND in both groups. DM patients had μHP lower than H sub-
jects at REST, but the two groups were indistinguishable during STAND (Fig 1a). μSAP was sig-
nificantly larger in the DM group than in H subjects both at REST and during STAND, but
STAND affected only the DM group (Fig 1b). The σ2HP was significantly reduced in DM group
both at REST and during STAND but the effect of STAND was visible only in the H group (Fig
1c). The σ2SAP did not distinguish the groups within the same experimental condition (Fig 1d).
While STAND increased σ2SAP in DM subjects, STAND did not influence σ
2
SAP in H subjects
(Fig 1d). The HFHP power was significantly smaller in DM patients than in H individuals at
REST, while the values of the HFHP power were similar in the two populations during STAND
Cardiovascular Oscillations Analysis in Type 2 Diabetes
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Fig 1. Univariate time and frequency domain analyses of HP and SAP series. The grouped bargraphs show the results of time and frequency domain
analyses of HP and SAP series as a function of the group (i.e. H and DM individuals) at REST (black bars) and during STAND (white bars). The graphs are
relevant to μHP (a), μSAP (b), σ
2
HP (c), σ
2
SAP (d), HFHP (e), and LFSAP (f). Values are given as mean plus standard deviation. The symbol * indicates
differences between groups (i.e. H vs DM) with p<0.05, while the symbol § indicates differences between experimental conditions (i.e. REST vs STAND) with
p<0.05.
doi:10.1371/journal.pone.0148903.g001
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(Fig 1e). The decrease of the HFHP power during STAND was remarkable in H subjects, while
it was negligible in DM patients (Fig 1e). LFSAP power did not separate the two groups but the
effect of STAND increasing the LFSAP power was visible in both H and DM individuals
(Fig 1f).
HP-SAP squared coherence and phase analyses
The grouped bargraphs of Fig 2 show the results of phase (Fig 2a and 2b) and squared coher-
ence (Fig 2c and 2d) analyses between HP and SAP series as a function of the group (i.e. H and
DM individuals) at REST (black bars) and during STAND (white bars). Values are given as
mean plus standard deviation. While PhHP-SAP(LF) is significantly smaller than 0 regardless of
the experimental condition (i.e. REST or STAND) and group (i.e. H or DM) (Fig 2a),
PhHP-SAP(HF) exhibited both positive and negative values (Fig 2b). Neither experimental con-
dition nor group affected PhHP-SAP(LF) and PhHP-SAP(HF) (Fig 2a and 2b). While
K2HP-SAP(HF) was not influenced by experimental condition or group (Fig 2d), K
2
HP-SAP(LF)
increased during STAND compared to REST in H group and it was significantly smaller in
Fig 2. HP-SAP squared coherence and phase analyses. The grouped bargraphs show the results of phase, PhHP-SAP, and squared coherence, K
2
HP-SAP,
analyses between HP and SAP series as a function of the group (i.e. H and DM individuals) at REST (black bars) and during STAND (white bars). The graphs
are relevant to PhHP-SAP(LF) (a), PhHP-SAP(HF) (b), K
2
HP-SAP(LF) (c), and K
2
HP-SAP(HF) (d). Values are given as mean plus standard deviation. The symbol
* indicates differences between groups (i.e. H vs DM) with p<0.05, while the symbol § indicates differences between experimental conditions (i.e. REST vs
STAND) with p<0.05.
doi:10.1371/journal.pone.0148903.g002
Cardiovascular Oscillations Analysis in Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0148903 March 17, 2016 8 / 14
DM group than in H subjects during STAND (Fig 2c). The prerequisite of significant K2HP-SAP
(i.e. larger than the threshold set with surrogate analysis) and PhHP-SAP smaller than 0 was ful-
filled in the LF band in more than 90% regardless of group and experimental condition. The
same prerequisite was fulfilled in the HF band in 73.53% of H subjects and 67.65% of DM
patients at REST and in 58.82% of H subjects and 55.88% of DM patients during STAND.
Assessment of BRS
The grouped bargraphs of Fig 3 show the BRS estimates (Fig 3a, 3b and 3d) as a function of the
group (i.e. H and DM individuals) at REST (black bar) and during STAND (white bars). The
percentage of baroreflex sequences, %SEQ, was reported as well (Fig 3c). Values are given as
mean plus standard deviation. All BRS estimates decreased during STAND regardless of the
group (i.e. in H or DM individuals). αHF and αSEQ was significantly smaller in DM patients
than in H subjects regardless of the experimental conditions (Fig 3b and 3d). αLF did not sepa-
rate groups within the same experimental condition (Fig 3a). The efficacy of the orthostatic
stimulus in both groups was confirmed by the increase of %SEQ during STAND regardless of
the group (Fig 3c). %SEQ distinguished the groups only during STAND (Fig 3c). Considering
Fig 3. Time and frequency domain BRS parameters. The grouped bargraphs show the BRS estimates as a function of the group (i.e. H and DM
individuals) at REST (black bars) and during STAND (white bars). The graphs are relevant to αLF (a), αHF (b), %SEQ (c), and αSEQ (d). Values are given as
mean plus standard deviation. The symbol * indicates differences between groups (i.e. H vs DM) with p<0.05, while the symbol § indicates differences
between experimental conditions (i.e. REST vs STAND) with p<0.05.
doi:10.1371/journal.pone.0148903.g003
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separately up and down BRS sequences did not lead to results significantly different from those
reported in Fig 3c and 3d.
Discussion
The main findings of this study are as follows: i) the HFHP power was lower in type 2 DM
patients than in H subjects at REST, while the two groups had comparable HFHP power during
STAND; ii) the LFSAP power was similar in type 2 DM patients and H subjects at REST and
increased during STAND in both groups; iii) αHF and αSEQ in type 2 DM group was smaller
than in H subjects at REST and both BRSs decreased during STAND.
Novelty of the selected type-2 DM group and of the protocol design
H and DM groups were similar in terms of age and antropometric characteristics. As expected,
they were different in relation to glycated hemoglobin (HbA1c), fasting plasma glucose, insulin
and triglycerides [28,29]. The main elements of novelty of the type 2 DM group are: i) it is com-
posed by non-smokers individuals that never smoked in their life; ii) it is composed by type 2
DM patients who were not affected by CAN and are asymptomatic for any type of neuropathy.
The absence of CAN was verified according to Ewing tests assessing the heart rate at REST, the
response of heart rate to slow deep breathing test, to STAND and Valsalva maneuver, the
orthostatic hypotension in reaction to STAND [18]. The absence of peripheral neuropathy and
other type of neuropathies was checked by evaluating the sensitivity to 10.0 g Semmes-Wein-
stein monofilament and by clinical anamnesis.
This special subgroup of type 2 DM patients was chosen because several studies observed
that smoking affected the magnitude of heart rate variability and BRS [30], and it was shown
that smoking negatively influences the autonomic control. It is well-known that individuals
with CAN exhibited lower BRS [3,31]. This impairment was attributed to the functional or
structural impairment of nerve fibers of the autonomic nervous system innervating the heart
and blood vessels [32]. In addition, the presence of other neuropathies, e.g. peripheral neuropa-
thy, was associated with a reduced BRS [8]. The selected population would allow us to assess
the effect of type 2 DM on the autonomic function and baroreflex control of heart rate per se in
absence of the confounding factors such as smoking and manifest neuropathies.
The element of originality of the experimental protocol lies in the exploitation of an active
postural maneuver (i.e. STAND), being an important daily life stressor of the cardiovascular
control [16,17] and easily applicable at the bedside in clinics. This maneuver has been used to
probe baroreflex control of heart rate and challenge cardiovascular homeostasis [16,33,34].
Indeed, this maneuver causes a reduction of the venous return triggering an increase of heart
rate and peripheral vascular resistance to maintain suitable values of arterial blood pressure
[35]. This response is mediated by a cardiac vagal withdrawal and vascular sympathetic activa-
tion leading to a decrease of the HFHP power and an increase of the LFSAP one in H population
[14,15]. These expected modification of the HFHP and LFSAP powers in response to STAND in
H subjects were confirmed in present study (Fig 1e and 1f), thus remarking the suitability of
this stimulus to probe autonomic control. In addition, STAND elicited between-group differ-
ences. Indeed, while the HFHP power significantly decreased in response to STAND in H sub-
jects, the decline was not visible in the DM group.
Time and frequency domain parameters in the type-2 DM group
The DM group featured a reduced μHP compared to the H subjects but preserved the tachycar-
dic response to STAND. In addition, the DM group was characterized by higher values of μSAP
due to the presence of 15 subjects (44.12%) with arterial hypertension controlled by medication
Cardiovascular Oscillations Analysis in Type 2 Diabetes
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(Tab.1). The HFHP power in the DM group was smaller than that in H subjects at REST and it
was not significantly modified by STAND. Conversely, the LFSAP power in the DM group was
similar in H subjects at REST and it was significantly increased by STAND in both groups.
These data allow us to conclude that the vagal control directed to the heart, as assessed by
HFHP, is impaired in DM patients, while the sympathetic control directed to the vessels, as esti-
mated by LFSAP, is preserved. This finding is in agreement with the original observation
reported in [36] showing that individuals with type 2 DM feature first a vagal nerve injury and,
later, a damage of the sympathetic fibers. Other study evaluating a DM population found a
reduced LFSAP power [6], but, at difference with the present study, their DM group included
individuals with CAN. Therefore, we conclude that the presence of CAN or other type of neu-
ropathies might be responsible for the additional impairment of the sympathetic control to the
vessels, while the vagal impairment is a primary result of type 2 DM. It is worth noting that
similar results were found in individuals with type 1 DM [37].
Baroreflex control of heart rate in type-2 DM group
αHF and αSEQ were significantly smaller in DM patients than in H subjects. This finding reveals
an impairment of baroreflex control of heart rate in DM group. Therefore, it seems that αHF
and αSEQ are sensitive enough to detect the baroreflex dysfunction in individuals with type 2
DM without CAN and asymptomatic for any other type of neuropathy. This result could not
be achieved using αLF, possibly due to a weaker statistical power of αLF compared to αHF and
αSEQ. It is remarkable that our DM group preserved the ability to reduce BRS during STAND.
Since in H subjects a decrease of BRS in response to STAND is expected [38] and it is con-
firmed by all BRS estimates computed in this study (Fig 3a, 3b and 3d), we suggest that the
response of cardiac baroreflex was maintained in DM patients. Since an impaired cardio-vagal
and vasomotor response to baroreceptor stimulation was found in subjects with type 2 DM
with more than two abnormal Ewing tests [7], we concluded that CAN and/or other neuropa-
thies might be responsible for the impairment of the baroreflex response to STAND, while type
2 DM per semight leave this ability unharmed.
Limitations of the study and future developments
One of the possible confounding factors of the study is that it is controlled in terms of CAN
and other neuropathies (i.e. their effect on the results are excluded) but it is not controlled for
other possible co-morbidities of type 2 DM. One of the co-morbidity is hypertension. However,
when analysis was carried out over the non-hypertensive group results were not significantly
different from those here reported, thus suggesting the that presence of a fraction of hyperten-
sive patients in the DM group did not influence the conclusions of the study. We advocate
studies specifically designed to rule out the impact of hypertension and hypertensive medica-
tions in a population of type 2 DM in absence of CAN and/or other neuropathies. Future stud-
ies should assess the potential effect of countermeasures in controlling and even reversing the
vagal autonomic dysfunction and to check whether the worsening effect of incoming neuropa-
thy over the autonomic function could depend on the type of neuropathy.
Conclusions
Individuals with type 2 DM without CAN and asymptomatic for any other type of neuropathy
featured an impairment of vagal regulation and the baroreflex control of heart rate, maintained
intact the sympathetic control directed to vessels and preserved the capability of cardiac baror-
eflex and sympathetic control to react to postural challenge. The autonomic control profile of
our DM patients is not favorable because a lower BRS reduces the ability of cardiac baroreflex
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to deal with large variations in arterial blood pressure and the reduced vagal modulation might
exert an insufficient restraint against sympathetic hyper-tone, thus exposing type 2 DM indi-
viduals without CAN and asymptomatic for any other type of neuropathy to risky situations
such as stroke and cardiac arrhythmias. We conclude that analysis of spontaneous fluctuations
of HP and SAP provide indexes sensitive enough to detect cardiovascular dysfunction in type 2
DM patients without CAN and asymptomatic for any other type of neuropathy and to typify it.
In addition, data suggest that type 2 DM affected per se baroreflex control of heart rate through
an impairment of vagal control.
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